Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Nanoparticle Delivery System for Ewing Sarcoma Treatment

Award Number: R41CA203457
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/15/2016
PERIOD OF PERFORMANCE END DATE: 03/31/2018

Group Awards By:

View Award Description

Nanoparticle Delivery System for Ewing Sarcoma Treatment - ¿ DESCRIPTION (provided by applicant): This Phase I STTR project seeks to demonstrate proof of principle that novel, targetable nanoparticles can delivery therapeutic substances to human tumor cells and reduce tumor burden in metastatic cancer. The concept for these nanoparticles is based on the polymerized liposome nanoparticle (PLN) that displays functional antibodies that target tumor cell surface markers. The therapeutic cargos are encapsulated cytotoxic drugs that comprise the front line treatment for Ewing sarcoma. Upon recognition by the tumor cell, the nanoparticle binds, gets taken into the cell (endocytosed) and the nanoparticle cargo is released, ultimately allowing availability of the drug to kill the cancer cel. This project fits well within the mission of the NCI, to develop new nanotechnology-based therapeutics. Treatment-resistant metastases are the ultimate cause of death in most cancer patients. Systemic therapy for metastases is generally ineffective. A reliable, low-toxic, highly effective therapy is urgently needed to treat both relapse patients and treatment- resistant metastases. The specific aims of this proposal are therefore to carry out efficient encapsulation of cancer drugs inside targeted PLNs and demonstrate efficacy in killing cancer cells in a xenograft mouse model of metastatic human Ewing sarcoma. NanoValent's goal, at the conclusion of the STTR Phase II is to assemble the necessary data for an IND submission to the FDA for approval of this novel therapy, initially for use in relapsed Ewing sarcoma patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2016	NANOVALENT PHARMACEUTICALS, INC.	910 TECHNOLOGY BLVD STE G	BOZEMAN	MT	59718	GALLATIN	USA	Cancer Treatment Research	000	1	7/6/2018	NEW	$0
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $240,750 )
2016	2016	NANOVALENT PHARMACEUTICALS, INC	910 TECHNOLOGY BLVD STE G	BOZEMAN	MT	59718	GALLATIN	USA	Cancer Treatment Research	000	1	4/15/2016	NEW	$240,750
														Subtotal = $240,750

Grand Total All Awards = $240,750

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Nanoparticle Delivery System for Ewing Sarcoma Treatment

Award Number: R41CA203457

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/15/2016

PERIOD OF PERFORMANCE END DATE: 03/31/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer